Artificial Intelligence (AI) Market

By offering, the hardware segment holds the largest revenue share in 2026, driven by the extraordinary capital investment being directed toward AI compute infrastructure. The investment in AI accelerator chips underscores the scale of financial commitment in the industry. In 2024, Amazon's capital expenditures exceeded USD 83 billion, with a significant portion allocated to AI-focused data center hardware. Similarly, Microsoft pledged USD 80 billion for infrastructure investment in fiscal 2025. By the end of 2024, Meta was operating the equivalent of 600,000 H100 GPUs. This level of spending is essential, reflecting the belief among hyperscalers and large enterprises that AI computing capacity is a strategic asset. The dominance of hardware revenue highlights the capital-intensive nature of the current phase of AI market development, where the primary limitation is physical infrastructure rather than software capabilities.

Generative AI is the fastest-growing technology segment within the AI market, and by a significant margin. The technology's ability to generate text, code, images, audio, and structured data from natural language instructions has made it applicable across nearly every business function. This includes areas such as content creation, software development, customer service, drug discovery, and financial analysis. MarketsandMarkets projects that the generative AI market, as part of the broader AI industry, will grow at a compound annual growth rate (CAGR) of 43.4%, outpacing other technology segments like machine learning, computer vision, and natural language processing. Among companies that have fully embraced AI-led processes, the percentage nearly doubled from 9% in 2023 to 16% in 2024. Generative AI plays a central role in all major functions, including IT, marketing, customer service, and finance.

Operations and supply chain management is expected to be the largest segment of the AI market by 2026. This makes sense from a business perspective, as most enterprise costs are found in operations. AI can optimize logistics, forecast demand, reduce waste, and manage supplier networks, leading to financial benefits that CFOs can quantify and justify. A notable example is General Mills, which has utilized AI models to analyze over 5,000 daily shipments. Since fiscal 2024, this initiative has led to savings of over a million USD in the supply chain, with an additional projected savings of USD 50 million from reducing manufacturing waste through real-time performance data. Across various industries—such as manufacturing, retail, logistics, and energy—companies are leveraging AI for demand forecasting, predictive maintenance, inventory optimization, route planning, and supplier risk management. As a result, operations have the widest range of monetizable AI applications.

The hybrid deployment model is the fastest-growing approach for distributing AI workloads, utilizing a combination of on-premises infrastructure, private cloud, and public cloud. This model is adapted based on factors such as data sensitivity, latency requirements, and cost. Its growth underscores the practical challenges enterprises face when scaling their AI solutions. In regulated industries, like banking, healthcare, and defense, data sovereignty requirements can complicate or even prohibit full cloud deployment. On the other hand, relying solely on on-premises infrastructure often lacks the flexibility needed to manage varying inference demands or to access the latest foundational model capabilities. The hybrid model effectively addresses these challenges by allowing enterprises to keep sensitive training data and proprietary models on-premises while leveraging cloud resources for scalability, experimentation, and access to third-party model APIs.

The healthcare & life sciences sector is the fastest-growing area in the AI market, primarily driven by advancements in drug discovery and precision medicine. AI addresses significant challenges in the pharmaceutical industry, particularly the high costs, lengthy timelines, and high failure rates associated with drug development. The traditional drug discovery process typically takes over 10 years, from target identification to clinical approval, and can exceed USD 2 billion for each approved drug, with about a 90% failure rate for candidates entering development. AI is significantly shortening the initial stages of this process. For example, Insilico Medicine progressed from novel target identification to Phase I clinical trial for its idiopathic pulmonary fibrosis drug, rentosertib, in under 30 months—approximately half the conventional timeline. Additionally, AI is being utilized for patient stratification, clinical trial optimization, and precision medicine applications, which match treatments to patient profiles more accurately than traditional methods.

Software and technology companies will constitute the largest end-user segment in the AI market by 2026. This trend reflects the early-mover advantage of technology firms and the inherent nature of AI capabilities, which are most directly integrated into software and technology products. These products then distribute AI technologies into other industries. Technology companies serve as primary customers and distributors of AI. They consume vast amounts of AI infrastructure; for instance, Microsoft, Google, Meta, and Amazon together account for a significant share of global AI hardware expenditure. At the same time, these companies incorporate AI into the products and platforms that enterprises in various sectors rely on. The software and technology segment also includes AI-native software companies that develop a range of products, from developer tools and data infrastructure to vertical SaaS solutions and autonomous agents.